In this commentary, I discuss several challenges when individualizing management of patients with HER2-negative early-stage breast cancer, from optimizing the tolerability of adjuvant CDK4/6 inhibitors to considering adjuvant olaparib for patients with low-/intermediate-risk disease.
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/challenges-for-her2neg-ebc/18940-28027
- Start Date: 2024-04-03 05:00:00
- End Date: 2024-04-03 05:00:00
- Credit Details: IPCE Credits: 0.25 hours
AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 25000.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 30000.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 48756.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest